4//SEC Filing
Q Therapeutics, Inc. 4
Accession 0001209191-15-070308
CIK 0001366541operating
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 3:20 PM ET
Size
10.2 KB
Accession
0001209191-15-070308
Insider Transaction Report
Form 4
Q Therapeutics, Inc.[NONE]
BORST STEVEN JOHN
CFO & VP of Corp. Development
Transactions
- Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+100,000$70,000→ 2,736,674 totalExercise: $0.70Exp: 2025-09-08→ Common Stock (100,000 underlying) - Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+100,000$70,000→ 2,636,674 totalExercise: $0.70Exp: 2025-09-08→ Common Stock (100,000 underlying) - Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+400,000$280,000→ 2,536,674 totalExercise: $0.70From: 2016-09-08Exp: 2025-09-08→ Common Stock (400,000 underlying)
Footnotes (3)
- [F1]Option shall vest at the rate of 28% on the one year anniversary of the grant date and 2% per month thereafter.
- [F2]Option will vest in full upon the closing of an equity and/or debt financing in the cumulative amount of $10 million on or prior to June 30, 2016.
- [F3]Option to vest in full upon the first patient dosed in the Company's Phase I clinical trial.
Documents
Issuer
Q Therapeutics, Inc.
CIK 0001366541
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001366541
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 3:20 PM ET
- Size
- 10.2 KB